Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baixiangdan is an investigational Traditional Chinese Medicine (TCM) herbal formula developed by Shandong University of Traditional Chinese Medicine for the treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The formula is designed based on the TCM principle of soothing the liver to address emotional and physical symptoms associated with the luteal phase of the menstrual cycle. It typically contains extracts from *Paeonia lactiflora* (Baishao), *Cyperus rotundus* (Xiangfu), and *Paeonia suffruticosa* (Danpi). Research suggests that Baixiangdan may exert its therapeutic effects by modulating the GABAergic and serotonergic systems, which are implicated in the pathophysiology of PMDD. It has been evaluated in Phase 1 safety trials and Phase 2 exploratory efficacy trials in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Baixiangdan.